TAT

Hitachi, Tohoku University and Kyoto University Become World's First to Establish Technology for Highly Efficient, High-quality Production of Actinium-225, a Material Required for Internal Radiation Therapy Called TAT

Retrieved on: 
Tuesday, October 19, 2021
Photon, Institute for Materials Research, Kyoto University, National university, Electronvolt, Association, Method, Adult, Tohoku University, Patient, Efficiency, Chemistry, Safety, Associate, Institute, Cancer, Appropriate Infrastructure Development Group, Electromagnetism, Security, Actinium-225, Nuclear medicine, KUR, Electromagnetic radiation, TAT, ELPH, European Association of Urology, KUCA, Uranium, Physics, Science, Continental Automotive Systems, Biology, Cell, Technology, Electron, Radium Girls, Medicine, Engineering, IMR, Thorium, TSE, Environment, Research institute, Radiation, Alpha, Plutonium, Quality of life, Research, Radium, Agriculture, Medical imaging, Pharmaceutical industry, Fine chemical, Fossil fuel, Microscope

Hitachi, Tohoku University, and Kyoto University will continue research and development efforts to bring this production technology into commercial use, to help put TAT into clinical practice and ultimately improve cancer patients' quality of life (QoL).

Key Points: 
  • Hitachi, Tohoku University, and Kyoto University will continue research and development efforts to bring this production technology into commercial use, to help put TAT into clinical practice and ultimately improve cancer patients' quality of life (QoL).
  • Hitachi makes effort to pursue research and development that promotes the Security & Safety (healthy and comfortable life for each individual) of society.
  • External radiation uses beams of radiation delivered outside the body to target cancer cells, while internal radiation involves internal delivery of radiation.
  • Research Center for Electron Photon Science (ELPH), Tohoku University Hidetoshi Kikunaga, Associate Professor
    Institute for Integrated Radiation and Nuclear Science, Kyoto University

ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225

Retrieved on: 
Monday, October 18, 2021
Leadership, Organization, Pleasure, TAT, Technology, Radiochemistry, Industry, Solution, National Nuclear Laboratory, Actinium-225, Antibody, Nuclear medicine, GMP, Marketing, Transport, BEI, DNA, Patient, GLOBE, Investment, Â, Radionuclide, CEO, ITM, Good manufacturing practice, Safety, Research, Memorandum of understanding, CNL, Medical imaging, Renewable energy

Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.

Key Points: 
  • Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.
  • ITM is a world leader in the development, production and global supply of radiotherapeutics and diagnostics, and maintains an evolving precision oncology pipeline.
  • Under the terms of the agreement, CNL will be responsible for the research and development as well as the production of Actinium-225.
  • CNL and ITM aim to leverage their capabilities towards establishing a continuous commercial supply of GMP-grade Actinium-225 for the global market.

ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225

Retrieved on: 
Monday, October 18, 2021
Research, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Other Science, Science, Oncology, Leadership, Organization, Pleasure, Technology, TAT, Radiochemistry, Industry, Solution, National Nuclear Laboratory, Actinium-225, Antibody, Nuclear medicine, GMP, Transport, Marketing, DNA, Patient, Investment, Â, Radionuclide, CEO, ITM, Good manufacturing practice, Safety, Research, Memorandum of understanding, CNL, Medical imaging, Renewable energy, ITM Isotope Technologies Munich SE, CNL, ITM ISOTOPE TECHNOLOGIES MUNICH SE, CNL

Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.

Key Points: 
  • Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.
  • ITM is a world leader in the development, production and global supply of radiotherapeutics and diagnostics, and maintains an evolving precision oncology pipeline.
  • Under the terms of the agreement, CNL will be responsible for the research and development as well as the production of Actinium-225.
  • CNL and ITM aim to leverage their capabilities towards establishing a continuous commercial supply of GMP-grade Actinium-225 for the global market.

Master Vendor Platform, a Rising Solution for Tail Spend Optimization, Says Beroe

Retrieved on: 
Thursday, October 14, 2021
Goal, Organization, CPG, Technology, Advertising, TAT, Machine learning, Risk, Compliance, Intelligence, Financial services, Accounting, Food, Medication, Map, Tail, Acquisition, Consultant, Online shopping, Risk management

With the surge of technology, the master vendor platform can effectively channel and optimize the tail spend purchases.

Key Points: 
  • With the surge of technology, the master vendor platform can effectively channel and optimize the tail spend purchases.
  • "Many businesses have begun to recognize the need for focussing technology to optimize tail spend management.
  • There are four ways of tail spend optimization: time-saving & increased compliance, management control, vendor consolidation, and cost savings & increased spend under management.
  • These are four definite ways technology-based master vendor platforms can optimize tail spend, giving organizations better control of their spending and providing them with more cost-saving opportunities.

Master Vendor Platform, a Rising Solution for Tail Spend Optimization, Says Beroe

Retrieved on: 
Thursday, October 14, 2021
Goal, Organization, CPG, Technology, Advertising, TAT, Machine learning, Risk, Compliance, Intelligence, Financial services, Accounting, Food, Medication, Map, Tail, Acquisition, Consultant, Online shopping, Risk management

RALEIGH, N.C., Oct. 14, 2021 /PRNewswire/ -- Various industry verticals like Pharmaceutical, Automotive, CPG, Aerospace, Food & Beverage, Banking, and Financial Services are continuously exploring tech-backed vendor platforms to observe maximum tail spend optimization.  

Key Points: 
  • With the surge of technology, the master vendor platform can effectively channel and optimize the tail spend purchases.
  • "Many businesses have begun to recognize the need for focussing technology to optimize tail spend management.
  • There are four ways of tail spend optimization: time-saving & increased compliance, management control, vendor consolidation, and cost savings & increased spend under management.
  • These are four definite ways technology-based master vendor platforms can optimize tail spend, giving organizations better control of their spending and providing them with more cost-saving opportunities.

Precision Molecular Announces Publication of Preclinical Data Detailing Use of PMI06, a PD-L1 Imaging Agent, to Quantify Accessible Target Levels in Solid Tumors to Guide Therapy

Retrieved on: 
Tuesday, September 28, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PET, Neoplasm, Johns Hopkins School of Medicine, Pharmacokinetics, Therapy, National academy, Cancer, Patient, Lists of diseases, Biomarker, TAT, Biopsy, CEO, PMI, Antibody, PD-1, National, PD-L1, Neurodegeneration, Survival, Radiation, PNAS, Pharmaceutical industry, Medical imaging, Palladium, PMI, D&D Pharmatech, PMI, D&D PHARMATECH

The study also demonstrated how accessible target levels can be used to derive insights into pharmacologic activity of antibodies in tumors and elucidate therapeutic response.

Key Points: 
  • The study also demonstrated how accessible target levels can be used to derive insights into pharmacologic activity of antibodies in tumors and elucidate therapeutic response.
  • PMI06 is a radiolabeled peptide that binds to PD-L1, marking the ligand for visualization using positron emission tomography (PET) imaging.
  • There are several approved immune checkpoint inhibitors currently available to patients and more in development, said Seulki Lee, Ph.D., CEO of PMI.
  • Precision Molecular (PMI) is a clinical-stage company with the mission to develop imaging biomarkers and targeted alpha therapy (TAT) for cancer management.

Matternet and SkyGo partner with Abu Dhabi DoH for world's first city-wide medical drone network

Retrieved on: 
Wednesday, September 22, 2021
Blood, News, PCR, Partnership, Emirate, Mission control center, Congestion, Abu Dhabi Department of Education and Knowledge, Department of Health (Abu Dhabi), 2019–20 Colorado drone sightings, Doh, Transport, JAL, COVID-19, Board of directors, Pharmacy, ABU, FAA, UPS Flight Forward, TAT, Future, COVID-19 vaccine, CEO, Knowledge, City, European Union, Wake Forest Baptist Medical Center, Delivery drone, Technology, UPS, Union, Organization, Terminal, Department

ABU DHABI, UAE, Sept. 22, 2021 /PRNewswire/ --Today, Matternet announced a city-wide drone delivery network for the rapid transport of medical goods in Abu Dhabi, in collaboration with the Abu Dhabi Department of Health (DoH) and logistics company Skygo .

Key Points: 
  • ABU DHABI, UAE, Sept. 22, 2021 /PRNewswire/ --Today, Matternet announced a city-wide drone delivery network for the rapid transport of medical goods in Abu Dhabi, in collaboration with the Abu Dhabi Department of Health (DoH) and logistics company Skygo .
  • To bring its services to Abu Dhabi, Matternet, the global leader in urban drone delivery, has partnered with SkyGo, a UAE company with in-depth knowledge of the Abu Dhabi healthcare landscape and expertise in logistics and distribution in the Gulf region.
  • Notably, last month Matternet became the first drone company in the U.S. to start transporting the Pfizer-BioNTech COVID-19 vaccine by drone.
  • In November 2020, Matternet initiated the first permanent BVLOS medical drone network in the European Union with Labor Berlin.

Samsung Foundry Certifies Synopsys PrimeLib Unified Library Characterization and Validation Solution at 5nm, 4nm and 3nm Process Nodes

Retrieved on: 
Wednesday, September 22, 2021
Cloud, Synopsys, Product marketing, SOC, Temperature, HSPICE, Prime time, Artificial intelligence, Solution, Ageing, Workload, Certification, Accreditation, PVT, TAT, IP, LVF, Silicon, HPC, Technology, PDK, Algorithm, Validation, Samsung Electronics, Digital, SNPS, VP, Nasdaq, EM, EDA, Cryptocurrency, Video game console

With compute demands growing 3x as each node advances, library characterization complexity has dramatically increased.

Key Points: 
  • With compute demands growing 3x as each node advances, library characterization complexity has dramatically increased.
  • The next-generation solution also includes innovative SmartScaling technology for multi-PVT characterization, built on top of the Synopsys PrimeTime scaling engine to enable instant library generation with minimum characterized corners.
  • "The Synopsys PrimeLib library characterization and validation solution enables us to deliver signoff-quality libraries for these advanced nodes up to 5x faster.
  • For more information, visit PrimeLib: Unified Library Characterization and Validation .

BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225

Retrieved on: 
Thursday, September 16, 2021
Biotechnology, Health, Stem Cells, Pharmaceutical, Oncology, People, Risk, U.S. Securities and Exchange Commission, Automation, Security (finance), Taipei, Radiopharmaceutical, TAT, Form 10-K, Prostate cancer, Nuclear medicine, United States Department of Energy, BWX Technologies, PSMA, Annual report, NYSE, Neoplasm, BWXT, Tat, Radium-223, NASA, Twitter, Radiation, Cancer, Actinium-225, Pharmaceutical industry, Medical imaging

BWXT Medical is a global supplier of medical isotopes and radiopharmaceuticals.

Key Points: 
  • BWXT Medical is a global supplier of medical isotopes and radiopharmaceuticals.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.
  • BWXT Medical plans to utilize its deep relationships with strategic partners in irradiation services and development of Ac-225.
  • Much like BWXT Medicals other products, processing and manufacturing would then be conducted at BWXT Medical facilities.